The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea

A randomised comparative trial

Nor Azlin Mohamed Ismail, I. Maryasalwati, M. N. Norzilawati, Zaleha Abdullah Mahdy, M. A. Jamil, Zainul Rashid Mohd. Razi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Dysmenorrhoea is painful menstruation that occurs in 45-72% of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia®) compared with mefenamic acid (Ponstan®) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80% (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid.

Original languageEnglish
Pages (from-to)424-426
Number of pages3
JournalJournal of Obstetrics and Gynaecology
Volume28
Issue number4
DOIs
Publication statusPublished - May 2008

Fingerprint

etoricoxib
Mefenamic Acid
Dysmenorrhea
Pain
Therapeutics
Cross-Over Studies

Keywords

  • Analgesia
  • Dysmenorrhoea
  • Etoricoxib
  • Mefenamic acid
  • Menorrhagia

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{660f67c3202944fda29f6e418ae54776,
title = "The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea: A randomised comparative trial",
abstract = "Dysmenorrhoea is painful menstruation that occurs in 45-72{\%} of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia{\circledR}) compared with mefenamic acid (Ponstan{\circledR}) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80{\%} (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid.",
keywords = "Analgesia, Dysmenorrhoea, Etoricoxib, Mefenamic acid, Menorrhagia",
author = "{Mohamed Ismail}, {Nor Azlin} and I. Maryasalwati and Norzilawati, {M. N.} and {Abdullah Mahdy}, Zaleha and Jamil, {M. A.} and {Mohd. Razi}, {Zainul Rashid}",
year = "2008",
month = "5",
doi = "10.1080/01443610802150051",
language = "English",
volume = "28",
pages = "424--426",
journal = "Asia-Oceania Journal of Obstetrics and Gynaecology",
issn = "1341-8076",
publisher = "Blackwell Publishing Asia",
number = "4",

}

TY - JOUR

T1 - The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhoea

T2 - A randomised comparative trial

AU - Mohamed Ismail, Nor Azlin

AU - Maryasalwati, I.

AU - Norzilawati, M. N.

AU - Abdullah Mahdy, Zaleha

AU - Jamil, M. A.

AU - Mohd. Razi, Zainul Rashid

PY - 2008/5

Y1 - 2008/5

N2 - Dysmenorrhoea is painful menstruation that occurs in 45-72% of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia®) compared with mefenamic acid (Ponstan®) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80% (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid.

AB - Dysmenorrhoea is painful menstruation that occurs in 45-72% of all women. This was a prospective randomised study of the efficacy of etoricoxib (Arcoxia®) compared with mefenamic acid (Ponstan®) in treating primary dysmenorrhoea. All single, sexually inactive women with primary dysmenorrhoea were randomised into two groups (mefenamic acid and etoricoxib) of pain relief and underwent a cross-over study. The success of treatment as evidenced by pain relief, the side-effects and complications were observed and analysed. Some 80% (20 women) had significantly better pain relief with etoricoxib, compared with only 20 per cent in the mefenamic acid group (p = 0.007). Etoricoxib has significantly fewer side-effects compared with mefenamic acid (p = 0.005) with significantly reduced menstrual blood loss (p = 0.025). In conclusion, etoricoxib is a better treatment for primary dysmenorrhoea with better pain relief, less menstrual blood loss and fewer side-effects compared with mefenamic acid.

KW - Analgesia

KW - Dysmenorrhoea

KW - Etoricoxib

KW - Mefenamic acid

KW - Menorrhagia

UR - http://www.scopus.com/inward/record.url?scp=46749110518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749110518&partnerID=8YFLogxK

U2 - 10.1080/01443610802150051

DO - 10.1080/01443610802150051

M3 - Article

VL - 28

SP - 424

EP - 426

JO - Asia-Oceania Journal of Obstetrics and Gynaecology

JF - Asia-Oceania Journal of Obstetrics and Gynaecology

SN - 1341-8076

IS - 4

ER -